

Natera shares are plunging Friday after mixed Q3 results, as a wider-than-expected loss offset revenue and guidance that topped estimates.
You can purchase shares of Natera (NASDAQ:NTRA) through any online brokerage.
Other companies in Natera’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Natera has a consensus price target of $340.95.
The stock price for Natera (NASDAQ: NTRA) is $311.2 last updated November 6, 2026 at 7:35 PM EST.
There are no upcoming dividends for Natera.
Natera does not have any upcoming earnings scheduled.
There is no upcoming split for Natera.
Natera is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a...